Literature DB >> 17338938

Pulmonary hypertension associated with left-sided heart disease.

Ronald J Oudiz1.   

Abstract

Pulmonary hypertension (PH) denotes a poor prognosis in patients with left-sided heart disease. No study has demonstrated long-term benefit from PH drugs such as prostanoids, endothelin antagonists, and phosphodiesterase-5 inhibitors. In some cases, cautious use of PH drugs may be indicated. However, theoretic and practical concerns limit any formal recommendations.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17338938     DOI： 10.1016/j.ccm.2006.12.001

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  35 in total

1.  Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis.

Authors:  Dimitry Schewel; Jury Schewel; Julia Martin; Lisa Voigtländer; Christian Frerker; Peter Wohlmuth; Thomas Thielsen; Karl-Heinz Kuck; Ulrich Schäfer
Journal:  Clin Res Cardiol       Date:  2014-11-04       Impact factor: 5.460

Review 2.  [Management of patients with pulmonary hypertension].

Authors:  B Preckel; S Eberl; J Fräßdorf; M W Hollmann
Journal:  Anaesthesist       Date:  2012-07       Impact factor: 1.041

Review 3.  Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 4.  Heart failure and pulmonary hypertension.

Authors:  Jordan T Shin; Marc J Semigran
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

5.  Maternal nutrient restriction during pregnancy and lactation leads to impaired right ventricular function in young adult baboons.

Authors:  Anderson H Kuo; Cun Li; Hillary F Huber; Matthias Schwab; Peter W Nathanielsz; Geoffrey D Clarke
Journal:  J Physiol       Date:  2017-05-18       Impact factor: 5.182

6.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 7.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

8.  An official American Thoracic Society Statement: pulmonary hypertension phenotypes.

Authors:  Raed A Dweik; Sharon Rounds; Serpil C Erzurum; Stephen Archer; Karen Fagan; Paul M Hassoun; Nicholas S Hill; Marc Humbert; Steven M Kawut; Michael Krowka; Evangelos Michelakis; Nicholas W Morrell; Kurt Stenmark; Rubin M Tuder; John Newman
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

9.  Computed axial tomography evidence of left atrial enlargement: a predictor of elevated pulmonary capillary wedge pressure in pulmonary hypertension.

Authors:  Z Safdar; Mf Katz; Ae Frost
Journal:  Int J Gen Med       Date:  2010-04-08

10.  Coronary Bypass Surgery in Patients with Pulmonary Hypertension: Assessment of Early and Long Term Results.

Authors:  Baris Akca; Nevzat Erdil; Olcay Murat Disli; Koksal Donmez; Feray Erdil; Mehmet Cengiz Colak; Bektas Battaloglu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-09       Impact factor: 1.520
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.